The relationship between Cho/NAA and glioma metabolism: implementation for margin delineation of cerebral gliomas

Jun Guo, Chengjun Yao, Hong Chen, Dongxiao Zhuang, Weijun Tang, Guang Ren, Yin Wang, Jinsong Wu, Fengping Huang, Liangfu Zhou, Jun Guo, Chengjun Yao, Hong Chen, Dongxiao Zhuang, Weijun Tang, Guang Ren, Yin Wang, Jinsong Wu, Fengping Huang, Liangfu Zhou

Abstract

Background: The marginal delineation of gliomas cannot be defined by conventional imaging due to their infiltrative growth pattern. Here we investigate the relationship between changes in glioma metabolism by proton magnetic resonance spectroscopic imaging ((1)H-MRSI) and histopathological findings in order to determine an optimal threshold value of choline/N-acetyl-aspartate (Cho/NAA) that can be used to define the extent of glioma spread.

Method: Eighteen patients with different grades of glioma were examined using (1)H-MRSI. Needle biopsies were performed under the guidance of neuronavigation prior to craniotomy. Intraoperative magnetic resonance imaging (MRI) was performed to evaluate the accuracy of sampling. Haematoxylin and eosin, and immunohistochemical staining with IDH1, MIB-1, p53, CD34 and glial fibrillary acidic protein (GFAP) antibodies were performed on all samples. Logistic regression analysis was used to determine the relationship between Cho/NAA and MIB-1, p53, CD34, and the degree of tumour infiltration. The clinical threshold ratio distinguishing tumour tissue in high-grade (grades III and IV) glioma (HGG) and low-grade (grade II) glioma (LGG) was calculated.

Results: In HGG, higher Cho/NAA ratios were associated with a greater probability of higher MIB-1 counts, stronger CD34 expression, and tumour infiltration. Ratio threshold values of 0.5, 1.0, 1.5 and 2.0 appeared to predict the specimens containing the tumour with respective probabilities of 0.38, 0.60, 0.79, 0.90 in HGG and 0.16, 0.39, 0.67, 0.87 in LGG.

Conclusions: HGG and LGG exhibit different spectroscopic patterns. Using (1)H-MRSI to guide the extent of resection has the potential to improve the clinical outcome of glioma surgery.

Figures

Fig. 1
Fig. 1
a T2-weighted MR image superimposed with coloured voxels from patient 4 with grade II astrocytoma. b Five voxels (T1, T2, T3, T4, T5) with IDs 197, 182, 167, 152, 137 corresponded to Cho/NAA ratio 0.73, 1.12, 2.12, 2.09, 1.16 respectively arranged from right to left were chosen by referring to the conventional MR images and local metabolic information together. c The five voxels were labelled in the neuronavigation data sets. d Positioning and calibration of navigation probe. e Skull-mounted trajectory guide guarantees the direction of biopsy needle. f The accurate sampling for needle biopsy was confirmed by intraoperative MR scanning
Fig. 2
Fig. 2
H & E (×400) and immunohistochemical staining with IDH-1, MIB-1, p53, CD34 and GFAP antibodies (×400, respectively) were performed respectively in each biopsy sample. The maximal Cho/NAA ratio (2.12) corresponded to the maximal value of cell density, MIB-1 and p53. The minimal Cho/NAA ratio (0.73) corresponded to the minimal value of cell density, MIB-1, and p53. All specimen were strong immunopositive for GFAP and moderate immunopositive for CD34, but immunonegative for IDH-1
Fig. 3
Fig. 3
Criteria for tumour infiltration. a Without tumour infiltration (normal brain or gliosis) (×400). b Mild tumour infiltration (low cell density, mild nuclear atypia) (×400). c Moderate tumour infiltration (moderate cell density, obvious nuclear atypia, few mitoses) (×400). d Heavy tumour infiltration (high cell density, obvious nuclear atypia, abundant mitoses) (×400)
Fig. 4
Fig. 4
Contrast-enhanced T1-weighted image superimposed with coloured voxels (upper middle) from patient 5 with glioblastoma multiforme. Seven voxels (T1, T2, T3, T4, T5, T6, T7) with IDs 43, 59, 75, 91, 107, 123, 139 arranged from left to right. A 3-D ideograph of the case (centre) rendered using Photoshop. H & E stained sections (×400) and MIB-1 (×400) showed the infiltration degree of T1, T6 and T7. Both T1 (upper left) and T6 (bottom) were located in IPR but had different Cho/NAA ratios. Histopathology confirmed that specimens from T1 and T6 were infiltrated differently. T1 and T7 (upper right) were located in IPR and DPR respectively but they shared the same Cho/NAA ratio and histopathology confirmed that specimens from T1 and T7 were infiltrated similarly

References

    1. Capper D, Sahm F, Hartmann C, Meyermann R, von Deimling A, Schittenhelm J. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol. 2010;34:1199–1204. doi: 10.1097/PAS.0b013e3181e7740d.
    1. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C, von Deimling A. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2010;20:245–254. doi: 10.1111/j.1750-3639.2009.00352.x.
    1. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 2009;118:599–601. doi: 10.1007/s00401-009-0595-z.
    1. Chen J, Huang SL, Li T, Chen XL. In vivo research in astrocytoma cell proliferation with 1H-magnetic resonance spectroscopy: correlation with histopathology and immunohistochemistry. Neuroradiology. 2006;48:312–318. doi: 10.1007/s00234-006-0066-3.
    1. Claus EB, Horlacher A, Hsu L, Schwartz RB, Dello-Iacono D, Talos F, Jolesz FA, Black PM. Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer. 2005;103:1227–1233. doi: 10.1002/cncr.20867.
    1. Croteau D, Scarpace L, Hearshen D, Gutierrez J, Fisher JL, Rock JP, Mikkelsen T. Correlation between magnetic resonance spectroscopy imaging and image-guided biopsies: semiquantitative and qualitative histopathological analyses of patients with untreated glioma. Neurosurgery. 2001;49:823–829.
    1. De Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med. 1995;34:721–727. doi: 10.1002/mrm.1910340511.
    1. Dowling C, Bollen AW, Noworolski SM, McDermott MW, Barbaro NM, Day MR, Henry RG, Chang SM, Dillon WP, Nelson SJ, Vigneron DB. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. AJNR Am J Neuroradiol. 2001;22:604–612.
    1. Farin A, Suzuki SO, Weiker M, Goldman JE, Bruce JN, Canoll P. Transplanted glioma cells migrate and proliferate on host brain vasculature: a dynamic analysis. Glia. 2006;53:799–808. doi: 10.1002/glia.20334.
    1. Ganslandt O, Stadlbauer A, Fahlbusch R, Kamada K, Buslei R, Blumcke I, Moser E, Nimsky C. Proton magnetic resonance spectroscopic imaging integrated into image-guided surgery: correlation to standard magnetic resonance imaging and tumor cell density. Neurosurgery. 2005;56(291–298):291–298. doi: 10.1227/01.NEU.0000156782.14538.78.
    1. Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg. 1987;66:865–874. doi: 10.3171/jns.1987.66.6.0865.
    1. Kemp GJ. Non-invasive methods for studying brain energy metabolism: what they show and what it means. Dev Neurosci. 2000;22:418–428. doi: 10.1159/000017471.
    1. Kimura T, Sako K, Gotoh T, Tanaka K, Tanaka T. In vivo single-voxel proton MR spectroscopy in brain lesions with ring-like enhancement. NMR Biomed. 2001;14:339–349. doi: 10.1002/nbm.711.
    1. Liu X, Germin BI, Zhong J, Ekholm S. N-Acetyl peak in MR spectra of intracranial metastatic mucinous adenocarcinomas. Magn Reson Imaging. 2010;28:1390–1394. doi: 10.1016/j.mri.2010.06.015.
    1. Matsumura A, Isobe T, Anno I, Takano S, Kawamura H. Correlation between choline and MIB-1 index in human gliomas. A quantitative in proton MR spectroscopy study. J Clin Neurosci. 2005;12:416–420.
    1. McKnight TR, Lamborn KR, Love TD, Berger MS, Chang S, Dillon WP, Bollen A, Nelson SJ. Correlation of magnetic resonance spectroscopic and growth characteristics within Grades II and III gliomas. J Neurosurg. 2007;106:660–666. doi: 10.3171/jns.2007.106.4.660.
    1. McKnight TR, von Dem BM, Vigneron DB, Lu Y, Berger MS, McDermott MW, Dillon WP, Graves EE, Pirzkall A, Nelson SJ. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg. 2002;97:794–802. doi: 10.3171/jns.2002.97.4.0794.
    1. Miller BL. A review of chemical issues in 1 H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. NMR Biomed. 1991;4:47–52. doi: 10.1002/nbm.1940040203.
    1. Mirbahai L, Wilson M, Shaw CS, McConville C, Malcomson RD, Griffin JL, Kauppinen RA, Peet AC. 1 H magnetic resonance spectroscopy metabolites as biomarkers for cell cycle arrest and cell death in rat glioma cells. Int J Biochem Cell Biol. 2011;43:990–1001. doi: 10.1016/j.biocel.2010.07.002.
    1. Momota H, Narita Y, Matsushita Y, Miyakita Y, Shibui S. p53 abnormality and tumor invasion in patients with malignant astrocytoma. Brain Tumor Pathol. 2010;27:95–101. doi: 10.1007/s10014-010-0272-x.
    1. Narayana A, Chang J, Thakur S, Huang W, Karimi S, Hou B, Kowalski A, Perera G, Holodny A, Gutin PH. Use of MR spectroscopy and functional imaging in the treatment planning of gliomas. Br J Radiol. 2007;80:347–354. doi: 10.1259/bjr/65349468.
    1. Park I, Bok R, Ozawa T, Phillips JJ, James CD, Vigneron DB, Ronen SM, Nelson SJ. Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13 C MR metabolic imaging. J Magn Reson Imaging. 2011;33:1284–1290. doi: 10.1002/jmri.22563.
    1. Pirzkall A, Li X, Oh J, Chang S, Berger MS, Larson DA, Verhey LJ, Dillon WP, Nelson SJ. 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI. Int J Radiat Oncol Biol Phys. 2004;59:126–137. doi: 10.1016/j.ijrobp.2003.08.023.
    1. Quinones-Hinojosa A, Sanai N, Smith JS, McDermott MW. Techniques to assess the proliferative potential of brain tumors. J Neurooncol. 2005;74:19–30. doi: 10.1007/s11060-004-5758-0.
    1. Rock JP, Hearshen D, Scarpace L, Croteau D, Gutierrez J, Fisher JL, Rosenblum ML, Mikkelsen T. Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurgery. 2002;51(912–919):919–920.
    1. Sabatier J, Gilard V, Malet-Martino M, Ranjeva JP, Terral C, Breil S, Delisle MB, Manelfe C, Tremoulet M, Berry I. Characterization of choline compounds with in vitro 1 H magnetic resonance spectroscopy for the discrimination of primary brain tumors. Invest Radiol. 1999;34:230–235. doi: 10.1097/00004424-199903000-00013.
    1. Sankar T, Caramanos Z, Assina R, Villemure JG, Leblanc R, Langleben A, Arnold DL, Preul MC. Prospective serial proton MR spectroscopic assessment of response to tamoxifen for recurrent malignant glioma. J Neurooncol. 2008;90:63–76. doi: 10.1007/s11060-008-9632-3.
    1. Schluter M, Stieltjes B, Hahn HK, Rexilius J, Konrad-verse O, Peitgen HO. Detection of tumour infiltration in axonal fibre bundles using diffusion tensor imaging. Int J Med Robot. 2005;1:80–86.
    1. Shaw EG, Wisoff JH. Prospective clinical trials of intracranial low-grade glioma in adults and children. Neuro Oncol. 2003;5:153–160. doi: 10.1215/S1152851702000601.
    1. Shimizu H, Kumabe T, Shirane R, Yoshimoto T. Correlation between choline level measured by proton MR spectroscopy and Ki-67 labeling index in gliomas. AJNR Am J Neuroradiol. 2000;21:659–665.
    1. Stadlbauer A, Buchfelder M, Doelken MT, Hammen T, Ganslandt O. Magnetic resonance spectroscopic imaging for visualization of the infiltration zone of glioma. Cen Eur Neurosurg. 2011;72:63–69. doi: 10.1055/s-0030-1253410.
    1. Stadlbauer A, Moser E, Gruber S, Buslei R, Nimsky C, Fahlbusch R, Ganslandt O. Improved delineation of brain tumors: an automated method for segmentation based on pathologic changes of 1 H-MRSI metabolites in gliomas. Neuroimage. 2004;23:454–461. doi: 10.1016/j.neuroimage.2004.06.022.
    1. Stadlbauer A, Nimsky C, Buslei R, Pinker K, Gruber S, Hammen T, Buchfelder M, Ganslandt O. Proton magnetic resonance spectroscopic imaging in the border zone of gliomas: correlation of metabolic and histological changes at low tumor infiltration—initial results. Invest Radiol. 2007;42:218–223. doi: 10.1097/01.rli.0000255812.61435.67.
    1. Udani V, Santarelli J, Yung Y, Cheshier S, Andrews A, Kasad Z, Tse V. Differential expression of angiopoietin-1 and angiopoietin-2 may enhance recruitment of bone-marrow-derived endothelial precursor cells into brain tumors. Neurol Res. 2005;27:801–806. doi: 10.1179/016164105X49319.
    1. Wang S, Fang J, Zhang T, Wang B, Chen J, Li X, Zhang S, Zhang W (2011) Magnetic resonance imaging targeting of intracranial glioma xenografts by Resovist-labeled endothelial progenitor cells. J Neurooncol 105:67-75
    1. Widhalm G, Krssak M, Minchev G, Wohrer A, Traub-Weidinger T, Czech T, Asenbaum S, Marosi C, Knosp E, Hainfellner JA, Prayer D, Wolfsberger S. Value of 1H-magnetic resonance spectroscopy chemical shift imaging for detection of anaplastic foci in diffusely infiltrating gliomas with non-significant contrast-enhancement. J Neurol Neurosurg Psychiatry. 2011;82:512–520. doi: 10.1136/jnnp.2010.205229.
    1. Yamahara T, Numa Y, Oishi T, Kawaguchi T, Seno T, Asai A, Kawamoto K. Morphological and flow cytometric analysis of cell infiltration in glioblastoma: a comparison of autopsy brain and neuroimaging. Brain Tumor Pathol. 2010;27:81–87. doi: 10.1007/s10014-010-0275-7.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir